MX2020010563A - Derivados de pirazolo-triazina y/o pirazolo-pirimidina farmaceuticamente activos. - Google Patents

Derivados de pirazolo-triazina y/o pirazolo-pirimidina farmaceuticamente activos.

Info

Publication number
MX2020010563A
MX2020010563A MX2020010563A MX2020010563A MX2020010563A MX 2020010563 A MX2020010563 A MX 2020010563A MX 2020010563 A MX2020010563 A MX 2020010563A MX 2020010563 A MX2020010563 A MX 2020010563A MX 2020010563 A MX2020010563 A MX 2020010563A
Authority
MX
Mexico
Prior art keywords
pyrazolo
pyrimidine derivatives
triazine
pharmaceutically active
diseases
Prior art date
Application number
MX2020010563A
Other languages
English (en)
Spanish (es)
Inventor
Jan Eickhoff
Gunther Zischinsky
Uwe Koch
Kiyean Nam
Jaeseung Kim
Yeejin Jeon
Dongsik Park
Donghoon Yu
Mooyoung Seo
Original Assignee
Qurient Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qurient Co Ltd filed Critical Qurient Co Ltd
Publication of MX2020010563A publication Critical patent/MX2020010563A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020010563A 2018-04-11 2019-04-11 Derivados de pirazolo-triazina y/o pirazolo-pirimidina farmaceuticamente activos. MX2020010563A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862656041P 2018-04-11 2018-04-11
PCT/EP2019/059289 WO2019197546A1 (en) 2018-04-11 2019-04-11 Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
MX2020010563A true MX2020010563A (es) 2020-10-22

Family

ID=66334384

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010563A MX2020010563A (es) 2018-04-11 2019-04-11 Derivados de pirazolo-triazina y/o pirazolo-pirimidina farmaceuticamente activos.

Country Status (14)

Country Link
US (1) US11858937B2 (https=)
EP (1) EP3774809A1 (https=)
JP (2) JP7406501B2 (https=)
KR (1) KR20200143429A (https=)
CN (1) CN112334471A (https=)
AU (1) AU2019250504B2 (https=)
BR (1) BR112020020645A2 (https=)
CA (1) CA3095426A1 (https=)
IL (2) IL299105B2 (https=)
MX (1) MX2020010563A (https=)
MY (1) MY207194A (https=)
PH (1) PH12020551638A1 (https=)
SG (1) SG11202009466UA (https=)
WO (1) WO2019197546A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
US20250263413A1 (en) * 2020-12-02 2025-08-21 Qurient Co., Ltd. Compounds having cyclin-dependent kinase(cdk)-inhibitory function
US20240343732A1 (en) * 2021-05-28 2024-10-17 Qurient Co., Ltd. Compounds for degradation of cyclin-dependent kinase 7(cdk7)
US20250042903A1 (en) * 2021-06-17 2025-02-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Triazine inhibitors of cyclin-dependent kinases
EP4493193A1 (en) * 2022-03-18 2025-01-22 Qurient Co., Ltd. Cdk7 inhibitors for antiviral treatment
US20260041693A1 (en) 2022-08-05 2026-02-12 Qurient Co., Ltd. Combination therapy of cdk7 inhibitors with other anti-cancer therapies
KR20240095030A (ko) 2022-12-15 2024-06-25 부산대학교 산학협력단 간과 신장의 염증 및 섬유화 치료 효과가 있는 신규 트리아진 유도체 및 이의 제조방법
CN120752238A (zh) * 2023-02-20 2025-10-03 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025040170A1 (zh) * 2023-08-24 2025-02-27 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025162425A1 (zh) * 2024-02-01 2025-08-07 广州费米子科技有限责任公司 吡唑并嘧啶化合物作为tyk2抑制剂
CN119606955A (zh) * 2024-11-13 2025-03-14 南方医科大学 Txd-174在制备治疗和/或预防黄病毒属病毒感染产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) * 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
EP2634189A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
EP3129371B1 (en) 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2899196T3 (es) * 2015-03-09 2022-03-10 Aurigene Discovery Tech Ltd Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK
WO2019035866A1 (en) * 2017-08-15 2019-02-21 The Brigham & Women's Hospital, Inc. COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX

Also Published As

Publication number Publication date
IL299105B2 (en) 2024-02-01
MY207194A (en) 2025-02-05
JP7406501B2 (ja) 2023-12-27
US11858937B2 (en) 2024-01-02
AU2019250504B2 (en) 2023-05-18
NZ768400A (en) 2024-07-05
CN112334471A (zh) 2021-02-05
SG11202009466UA (en) 2020-10-29
BR112020020645A2 (pt) 2021-01-12
US20210139483A1 (en) 2021-05-13
EP3774809A1 (en) 2021-02-17
WO2019197546A1 (en) 2019-10-17
IL299105A (en) 2023-02-01
AU2019250504A1 (en) 2020-10-15
JP2023138859A (ja) 2023-10-02
CA3095426A1 (en) 2019-10-17
PH12020551638A1 (en) 2021-07-26
KR20200143429A (ko) 2020-12-23
IL299105B1 (en) 2023-10-01
IL277694A (en) 2020-11-30
JP2021521129A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
MX2020010563A (es) Derivados de pirazolo-triazina y/o pirazolo-pirimidina farmaceuticamente activos.
MX2020010675A (es) Derivados de pirazolo-triazina y/o pirazolo-pirimidina como inhibidor selectivo de cinasa dependiente de ciclina.
CO2021016594A2 (es) Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina
MX2014010494A (es) Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
UY33286A (es) Derivados de triazina disustituidos farmaceuticamente activos
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CL2019002150A1 (es) Derivados de 3-fenil-4-amino-imidazo[4,5-c]piridin-2-ona y 7-fenil-6-amino-purin-8-ona sustituidos, inhibidores de tirosinacinasas, en particular tirosinacinasa de bruton (btk); composiciones que contiene los compuestos; y uso para enfermedades tales como cáncer, autoinmunitarias, inflamatorias y tromboembólicas. (divisional solicitud 201703073)
MX385576B (es) Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
MX381849B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
GEAP202215630A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
CL2012000059A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras.
PE20150187A1 (es) Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
AR101261A1 (es) Compuesto de tetrahidropirrolo[1,2:3,4]imidazo[1,2-c]pirimidin-1(6h)-ona y composición farmacéutica que lo comprende
CO2022001257A2 (es) 1,2,4]triazolo[1,5-c]quinazolin-5-aminas
CO2023007677A2 (es) Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btk
MX2019005123A (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2.
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
MX2020007443A (es) Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias.
MX2019005115A (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2.
EA201792087A1 (ru) ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА